NCT00319189View on ClinicalTrials.gov

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

November 30, 2003

Conditions
Renal Transplant RecipientsPosttransplant Diabetes MellitusPosttransplant Impaired Glucose Tolerance
Interventions
DRUG

Nateglinide

Trial Locations (1)

0027

Rikshospitalet, Section of Nephrology, Oslo

All Listed Sponsors
lead

University of Oslo School of Pharmacy

OTHER

NCT00319189 - Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter